The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market that investors have been skeptical BridgeBio can win.

biopharmadive.com

BridgeBio heart drug approved by FDA, setting up battle with Pfizer

Revolutionary Drug Approvals and Global Health Updates  In a groundbreaking development, the U.S. Food and Drug Administration has approved BridgeBio's novel treatment for a rare heart condition. This drug, known as Attruby, marks a significant advancement in the realm of cardiomyopathy treatments, presenting an alternative to Pfizer's major player, Vyndaqel.In another intriguing health update, studies reveal that healthy breast cells might poss…

Devdiscourse

Revolutionary Drug Approvals and Global Health Updates

BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more here.

Media Bias/Fact Check

Seeking Alpha

United States

Pfizer amyloidosis rival from BridgeBio wins FDA nod (PFE:NYSE)

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam
The FDA approved BridgeBio’s acoramidis in a rare, genetic heart disease that’s expected to become an intense area of market competition, and a broad label …

BizToc

FDA approves BridgeBio’s heart disease drug, setting up competition with Pfizer, Alnylam

BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted. The post BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug appeared first on Investor's Business Daily.

All Sides

Investor's Business Daily

BridgeBio Soars After FDA OKs Rival To Pfizer's Heart Drug

The FDA cleared Attruby to treat patients with the heart condition known as transthyretin amyloid cardiomyopathy, or ATTR-CM.

Ad Fontes Media

STAT

The Boston Globe

Boston

Suffolk County

Massachusetts

BridgeBio wins FDA approval for heart disease drug

Green Stock News for the New Green Economy.

Green Stock News

BridgeBio Pharma: Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

(Reuters) -The U.S. Food and Drug Administration has approved BridgeBio’s drug for a rare and deadly heart condition, the company said on Friday, making it the first new treatment in a market dominated by Pfizer’s blockbuster Vyndaqel. The oral drug, branded as Attruby, was approved to treat adult patients with transthyretin amyloid cardiomyopathy (ATTR-CM), in which faulty transthyretin proteins accumulate in the heart and can cause the organ t…

regionalmedianews.com

US FDA approves BridgeBio’s drug for rare heart condition - Regional Media News

JHVEPhoto   The U.S. FDA late Friday authorized BridgeBio Pharma’s ( NASDAQ: BBIO) lead possession Attruby for the unusual heart condition transthyretin heart amyloidosis in a prospective obstacle to Pfizer ( NYSE: PFE), which currently markets Vyndaqel, a competing treatment for the illness.  According to the       Source:  Business Insider. The post Pfizer amyloidosis rival from BridgeBio wins FDA nod (PFE:NYSE) appeared first on The New York …

The New York Ledger

The FDA approved BridgeBio’s ​​acoramidis in a rare, genetic heart disease that’s expected to become an intense area of market competition, and a broad label will give it a near-immediate boost against the current leader ...

Endpoints News

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

BridgeBio grabs FDA approval for its ATTR cardiomyopathy drug Attruby, setting up a challenge to market leader Pfizer.

BridgeBio heart drug approved by FDA, setting up battle with Pfizer

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics